Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of disease-modifying anti-rheumatic drugs.

Best practice & research. Clinical rheumatology - 1 Apr 2004

Tanaka E, Taniguchi A, Urano W, Yamanaka H, Kamatani N

Abstract excerpt

The outcome of treatment with disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients is considerably variable and is also unpredictable. It would be useful clinically if physicians were able to predict responses to DMARDs prior to their administration. One possible cause of differences in efficacy and adverse drug reactions is genetic variation in how individuals metabolize drugs....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antirheumatic Agents
Share to Arthritis, Rheumatoid
Share to Biochemical and Molecular Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Variation

Share to HIV/AIDS drug development and treatment

Share to Pharmacogenetics

Share to Rheumatoid Arthritis Research and Therapies

Source

Identifiers

PMID: 15121042
DOI: 10.1016/j.berh.2004.02.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of disease-modifying anti-rheumatic drugs.PMID 15121042Read ↗

Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: towards personalized medicine.Semantic proximity Read ↗

Genetic polymorphisms affect efficacy and adverse drug reactions of DMARDs in rheumatoid arthritis.Semantic proximity Read ↗

Pharmacogenetics in treatment of rheumatoid arthritis.Semantic proximity Read ↗

Pharmacogenetics of therapies in rheumatoid arthritis: An update.Semantic proximity Read ↗

Pharmacogenetics and pharmacogenomics in rheumatology.Semantic proximity Read ↗

Polymorphisms Involved in Response to Biological Agents Used in Rheumatoid Arthritis.Semantic proximity Read ↗

Methotrexate pharmacogenetics in rheumatoid arthritis: a status report.Semantic proximity Read ↗

Pharmacogenomics in rheumatoid arthritis.Semantic proximity Read ↗

Biomarkers to Personalize the Treatment of Rheumatoid Arthritis: Focus on Autoantibodies and PharmacogeneticsSemantic proximity Read ↗

The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy.Semantic proximity Read ↗

Pharmacogenomics of biological treatment in rheumatoid arthritis.Semantic proximity Read ↗

Using pharmacogenetics to predict methotrexate response in rheumatoid arthritis patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.